GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » EBITDA Margin %

Nevro (NVRO) EBITDA Margin % : -14.27% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Nevro EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nevro's EBITDA for the three months ended in Mar. 2024 was $-14.5 Mil. Nevro's Revenue for the three months ended in Mar. 2024 was $101.9 Mil. Therefore, Nevro's EBITDA margin for the quarter that ended in Mar. 2024 was -14.27%.


Nevro EBITDA Margin % Historical Data

The historical data trend for Nevro's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro EBITDA Margin % Chart

Nevro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.36 -14.42 -26.47 5.17 -18.42

Nevro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.62 -18.24 -18.17 -7.85 -14.27

Competitive Comparison of Nevro's EBITDA Margin %

For the Medical Devices subindustry, Nevro's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nevro's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nevro's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nevro's EBITDA Margin % falls into.



Nevro EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nevro's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-78.31/425.174
=-18.42 %

Nevro's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-14.546/101.899
=-14.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nevro  (NYSE:NVRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Nevro EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nevro's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nevro (NVRO) Business Description

Traded in Other Exchanges
Address
1800 Bridge Parkway, Redwood City, CA, USA, 94065
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Executives
Greg Siller officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick director 9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal officer: President & CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter officer: Chief Accounting Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid officer: General Counsel C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman director, officer: President & CEO
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane director, officer: Chief Executive Officer MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel director 3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod officer: Chief Financial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz officer: Vice President, Operations C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065